Beucal D500 mg+200 IU

Beucal D 500 mg+200 IU is a combined mineral and vitamin supplement in which calcium carbonate supplies elemental calcium and vitamin D3 (cholecalciferol) promotes intestinal absorption of that calcium. It is used for the following indications, classified by strength of evidence:

Established / Guideline-Supported Uses

• Prevention and treatment of calcium and vitamin D deficiency, including dietary insufficiency, in adults and children who cannot meet requirements through diet alone.
• Adjunct in the prevention and management of osteoporosis, particularly in postmenopausal women, elderly individuals, and patients on long-term corticosteroid therapy, where Beucal D 500 mg+200 IU is used together with (not as a replacement for) specific anti-osteoporotic therapy such as bisphosphonates when indicated.
• Supportive therapy in osteomalacia and rickets due to nutritional calcium/vitamin D deficiency.
• Calcium/vitamin D supplementation during pregnancy and lactation when dietary intake is inadequate, as directed by a physician.

Adjunct / Combination-Therapy Uses

• As a calcium and vitamin D supplement alongside disease-specific treatment in secondary hyperparathyroidism associated with vitamin D deficiency, and as a calcium supplement in chronic kidney disease under medical supervision (used together with, not instead of, phosphate binders or active vitamin D analogues where those are separately indicated).

Beucal D 500 mg+200 IU does not treat the underlying cause of bone disease and is not a substitute for prescription osteoporosis medication when that is required; it is intended to correct or prevent deficiency and to support bone health as directed by a physician.

Each unit of Beucal D 500 mg+200 IU typically contains calcium carbonate equivalent to a stated amount of elemental calcium (commonly 500–600 mg elemental calcium per tablet) together with vitamin D3 (cholecalciferol), commonly 200–400 IU per tablet. Exact strengths vary by brand and formulation; refer to the specific product label for the precise elemental calcium and vitamin D3 content.

Beucal D 500 mg+200 IU is an oral combination supplement of calcium carbonate (a calcium salt that provides elemental calcium) and vitamin D3 (cholecalciferol, the form of vitamin D naturally synthesized in human skin). It is available as tablets, chewable tablets, or effervescent formulations and is widely used to prevent and correct calcium and vitamin D deficiency and to support bone mineral health.

Calcium is essential for bone mineralization, muscle contraction, nerve transmission, and blood coagulation. Vitamin D3 is required for efficient intestinal absorption of calcium and for regulation of calcium and phosphate homeostasis; without adequate vitamin D, a large proportion of dietary or supplemental calcium is poorly absorbed.

Beucal D 500 mg+200 IU belongs to the therapeutic class of Minerals and Vitamins – Calcium and Vitamin D combinations, used as nutritional supplements and bone-health agents.

Beucal D 500 mg+200 IU combines two agents with complementary mechanisms:

• Calcium carbonate dissociates in the acidic environment of the stomach to release calcium ions, which are absorbed in the small intestine (mainly duodenum and jejunum) by both active vitamin D–dependent transport and passive paracellular diffusion. Elemental calcium is used for bone and tooth mineralization, and is essential for normal function of nerves, muscles (including cardiac muscle), and the blood-clotting cascade. Because calcium carbonate requires gastric acid for dissolution, absorption is improved when it is taken with food.
• Vitamin D3 (cholecalciferol) is hydroxylated in the liver to 25-hydroxyvitamin D and then in the kidney to the active hormone 1,25-dihydroxyvitamin D (calcitriol). Calcitriol increases intestinal absorption of calcium and phosphate, promotes renal calcium reabsorption, and works with parathyroid hormone to maintain normal serum calcium and support bone mineralization and remodeling.

Together, the components of Beucal D 500 mg+200 IU increase net calcium absorption and availability more effectively than calcium alone, supporting bone mineral density and reducing the risk of deficiency-related bone disease.

Beucal D 500 mg+200 IU should be taken orally, preferably with or right after meals to enhance absorption of calcium carbonate. Doses should be spaced apart from other medicines that interact with calcium or vitamin D (see Interaction). Chewable tablets should be chewed thoroughly; effervescent forms should be dissolved fully in water before drinking.

Beucal D 500 mg+200 IU has the following well-established, clinically significant interactions:

• Tetracycline antibiotics (e.g. tetracycline, doxycycline, minocycline): calcium chelates with tetracyclines in the gut, substantially reducing antibiotic absorption. Separate dosing by at least 2–3 hours.
• Bisphosphonates (e.g. alendronate, risedronate): calcium markedly reduces oral bisphosphonate absorption. Take bisphosphonates at least 30–60 minutes before Beucal D 500 mg+200 IU or any calcium-containing product.
• Levothyroxine and other thyroid hormone replacement: calcium can reduce absorption of levothyroxine. Separate administration by at least 4 hours.
• Thiazide diuretics: reduce renal calcium excretion and, when combined with Beucal D 500 mg+200 IU, increase the risk of hypercalcemia; concurrent use requires monitoring of serum calcium.
• Digoxin: hypercalcemia arising from excessive use of Beucal D 500 mg+200 IU can increase the risk of digoxin-related cardiac arrhythmia; avoid hypercalcemia in patients on digoxin.
• Other calcium or vitamin D–containing products (including calcitriol and other active vitamin D analogues, or antacids containing calcium/magnesium/aluminum): concurrent use increases the risk of hypercalcemia and can also independently reduce absorption of other oral drugs; avoid duplicate supplementation and space dosing from other antacids.
• Fluoroquinolone antibiotics (e.g. ciprofloxacin): calcium reduces fluoroquinolone absorption; separate dosing by at least 2 hours before or 6 hours after.

Beucal D 500 mg+200 IU is generally well tolerated at recommended doses. Reported adverse effects include:

• Common: constipation, bloating, flatulence, and mild gastrointestinal upset.
• Less common: nausea, vomiting, dry mouth, and increased thirst.
• Rare (usually with excessive/prolonged high-dose use): hypercalcemia (symptoms may include increased thirst, increased urination, fatigue, muscle weakness, confusion), hypercalciuria, and nephrolithiasis (kidney stones). See Precautions and Warnings.

Calcium and vitamin D supplementation at recommended doses is commonly used and considered beneficial during pregnancy and lactation to meet increased maternal and fetal/infant requirements. However, Beucal D 500 mg+200 IU should be used only as directed by a physician, and doses above those recommended for pregnancy/lactation should be avoided, as excessive intake may pose risks. A physician should individualize the dose based on dietary calcium intake, trimester, and any pre-existing conditions (e.g. renal impairment).

The following precautions apply to use of Beucal D 500 mg+200 IU:

• Take with food, as gastric acid is required for adequate dissolution and absorption of calcium carbonate.
• Use with caution in patients with a history of kidney stones, renal impairment, sarcoidosis, or other conditions predisposing to hypercalcemia or hypercalciuria; calcium and vitamin D levels should be monitored periodically during prolonged high-dose use.
• Avoid prolonged use of high doses, particularly in combination with thiazide diuretics or other vitamin D/calcium products, due to increased risk of hypercalcemia (see Interaction).
• Space dosing from tetracyclines, fluoroquinolones, bisphosphonates, and levothyroxine, which can have reduced absorption when taken together with calcium (see Interaction).
• Beucal D 500 mg+200 IU is not an antibiotic and carries no antimicrobial stewardship requirement, but should still be taken exactly as directed and not shared with others without medical advice, since individual dosing needs vary.

Overdose or prolonged excessive use of Beucal D 500 mg+200 IU can cause hypercalcemia and hypervitaminosis D, with symptoms such as nausea, vomiting, constipation, abdominal pain, excessive thirst, frequent urination, muscle weakness, confusion, and, in severe cases, cardiac arrhythmia or renal impairment. If overdose is suspected, seek immediate medical attention or contact a poison control center/emergency services; do not attempt specific home treatment. Management is supportive and should be directed by a healthcare professional, and may include stopping the supplement, hydration, and monitoring of serum calcium under medical care.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Beucal D 500 mg+200 IU may be used in children to prevent or treat calcium/vitamin D deficiency, using age-appropriate, weight-based dosing and formulations (e.g. chewable tablets or oral suspension) intended for pediatric use; safety and efficacy of adult-strength tablet formulations have not been established in young children. See Pediatric Uses.

Elderly

Beucal D 500 mg+200 IU is commonly used in elderly patients for prevention and adjunct management of osteoporosis, as this population is at higher risk of both deficiency and fracture. Renal function should be considered, as elderly patients may have reduced renal calcium clearance and higher hypercalcemia risk.

Renal Impairment

Use with caution and physician supervision in mild-to-moderate renal impairment; contraindicated in severe renal impairment with hypercalcemia risk (see Contraindications).

Hepatic Impairment

No well-established dose adjustment is required for hepatic impairment, but vitamin D metabolism may be altered in significant hepatic disease; use under medical supervision.

Duration of Beucal D 500 mg+200 IU therapy depends on the indication: short-term correction of dietary deficiency may require weeks to a few months, while use as an adjunct for osteoporosis prevention/management, or during pregnancy and lactation, is typically continued long-term as directed by a physician, with periodic reassessment of dietary intake, bone health, and (for prolonged high-dose use) serum calcium.

Calcium supplement; Vitamin D analogue; combination mineral–vitamin bone-health supplement.

Beucal D 500 mg+200 IU acts by supplying elemental calcium (from calcium carbonate) for bone mineralization and normal neuromuscular and cardiac function, while vitamin D3 (cholecalciferol) is converted in the liver and kidney to active calcitriol, which enhances intestinal absorption of the supplied calcium and helps regulate calcium-phosphate homeostasis, together supporting bone mineral density and correcting calcium/vitamin D deficiency.

Beucal D 500 mg+200 IU is used in children for prevention and treatment of dietary calcium and vitamin D deficiency and for support of normal bone mineralization, using pediatric-appropriate formulations and weight/age-based dosing as advised by a pediatrician. Safety and efficacy of specific adult tablet strengths have not been established for infants and young children; an age-appropriate formulation (e.g. chewable or liquid) should be used in this age group. Chronic excessive dosing should be avoided in children due to the risk of hypercalcemia and impaired growth.